Современные подходы к суицидальной генотерапии злокачественных новообразований

Обложка

Цитировать

Полный текст

Аннотация

   Одним из перспективных направлений противоопухолевой терапии является суицидальная генотерапия, основанная на внедрении в опухолевые клетки цитотоксических генов. Чаще всего это гены ферментов бактериального или вирусного происхождения, способные напрямую или опосредованно уничтожать клетки опухоли. В настоящем обзоре представлены сведения о современных стратегиях суицидальной генотерапии злокачественных новообразований, описаны их достоинства и недостатки, а также проанализированы свойства потенциального кандидата для создания на его основе новой высокоэффективной суицидальной системы, совмещающей в себе достоинства уже существующих подходов.

Об авторах

Е. В. Дудкина

ФГАОУ ВО «Казанский (Приволжский) федеральный университет»

Email: fake@neicon.ru
ORCID iD: 0000-0002-2817-1384

420008; ул. Кремлевская, 18; Казань

Россия

В. В. Ульянова

ФГАОУ ВО «Казанский (Приволжский) федеральный университет»

Автор, ответственный за переписку.
Email: ulyanova.vera@gmail.com
ORCID iD: 0000-0003-1768-3314

Вера Владимировна Ульянова

420008; ул. Кремлевская, 18; Казань

Россия

О. Н. Ильинская

ФГАОУ ВО «Казанский (Приволжский) федеральный университет»

Email: fake@neicon.ru
ORCID iD: 0000-0001-6936-2032

420008; ул. Кремлевская, 18; Казань

Россия

Список литературы

  1. Pottier C., Fresnais M., Gilon M. et al. Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers (Basel) 2020;12(3):731. doi: 10.3390/cancers12030731
  2. Zinn S., Vazquez-Lombardi R., Zimmermann C. et al. Advances in antibody-based therapy in oncology. Nat Cancer 2023;4(2):165–80. doi: 10.1038/s43018-023-00516-z
  3. Weiss F., Lauffenburger D., Friedl P. Towards targeting of shared mechanisms of cancer metastasis and therapy resistance. Nat Rev Cancer 2022;22(3):157–73. doi: 10.1038/s41568-021-00427-0
  4. Sun W., Shi Q., Zhang H. et al. Advances in the techniques and methodologies of cancer gene therapy. Discov Med 2019;27(146): 45–55.
  5. Cesur-Ergün B., Demir-Dora D. Gene therapy in cancer. J Gene Med 2023;25(11):e3550. doi: 10.1002/jgm.3550
  6. Navarro S.A., Carrillo E., Griñán-Lisón C. et al. Cancer suicide gene therapy : a patent review. Expert Opin Ther Pat 2016;26:1095–104. doi: 10.1080/13543776.2016.1211640
  7. Sheikh S., Ernst D., Keating A. Prodrugs and prodrug-activated systems in gene therapy. Mol Ther 2021;29(5):1716–28. doi: 10.1016/j.ymthe.2021.04.006
  8. Ardini M., Vago R., Fabbrini M.S., Ippoliti R. From immunotoxins to suicide toxin delivery approaches: is there a clinical opportunity? Toxins (Basel) 2022;14(9):579. doi: 10.3390/toxins14090579
  9. Tamura R., Miyoshi H., Yoshida K. et al. Recent progress in the research of suicide gene therapy for malignant glioma. Neurosurg Rev 2021;44(1):29–49. doi: 10.1007/s10143-019-01203-3
  10. Hong S., Zhang P., Zhang H. et al. Enforced effect of tk-MCP-1 fusion gene in ovarian cancer. J Exp Clin Cancer Res 2012;31(1):74. doi: 10.1186/1756-9966-31-74
  11. Alekseenko I.V., Snezhkov E.V., Chernov I.P. et al. Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer. J Transl Med 2015;13:78. doi: 10.1186/s12967-015-0433-0
  12. Liu Y., Sukumar U.K., Jugniot N. et al. Inhaled gold nano-star carriers for targeted delivery of triple suicide gene therapy and therapeutic microRNAs to lung metastases: development and validation in a small animal model. Adv Ther (Weinh) 2022;5(8):2200018. doi: 10.1002/adtp.202200018
  13. Ding Y., Fan J., Deng L. et al. Antitumor efficacy of cytosine deaminase-armed vaccinia virus plus 5-fluorocytosine in colorectal cancers. Cancer Cell Int 2020;20:243. doi: 10.1186/s12935-020-01340-6
  14. Emamian M., Abbaspour A., Shahani T et al. Non-viral suicide gene therapy: cytosine deaminase gene directed by VEGF promoter and 5-fluorocytosine as a gene directed enzyme/prodrug system in breast cancer model. Drug Res (Stuttg) 2021;71(7):395–406. doi: 10.1055/a-1488-6054
  15. Takahashi M., Valdes G., Hiraoka K. et al. Radiosensitization of gliomas by intracellular generation of 5-fluorouracil potentiates prodrug activator gene therapy with a retroviral replicating vector. Cancer Gene Ther 2014;21(10):405–10. doi: 10.1038/cgt.2014.38
  16. El-Sayed A.S.A., Mohamed N.Z., Yassin M.A. et al. Microbial cytosine deaminase is a programmable anticancer prodrug mediating enzyme: antibody, and gene directed enzyme prodrug therapy. Heliyon 2022;8(9):e10660. doi: 10.1016/j.heliyon.2022.e10660
  17. Ostertag D., Amundson K.K., Lopez Espinoza F. et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neuro Oncol 2012;14(2):145–59. doi: 10.1093/neuonc/nor199
  18. Vermes A., Guchelaar H.J., Dankert J. Flucytosine : a review of its pharmacology, clinical indications, pharmacokinetics, toxicity and drug interactions. J Antimicrob Chemother 2000;46(2):171–9. doi: 10.1093/jac/46.2.171
  19. Mitchell L.A., Lopez Espinoza F., Mendoza D. et al. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. Neuro Oncol 2017;19(7):930–9. doi: 10.1093/neuonc/nox037
  20. Cloughesy T.F., Petrecca K., Walbert T. et al. Effect of vocimagene amiretrorepvec in combination with flucytosine vs standard of care on survival following tumor resection in patients with recurrent high-grade glioma: a randomized clinical trial. JAMA Oncol 2020;6(12):1939–46. doi: 10.1001/jamaoncol.2020.3161
  21. Kazlauskas A., Darinskas A., Meškys R. et al. Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy. BMC Cancer 2019;19(1):197. doi: 10.1186/s12885-019-5409-7
  22. Vosough P., Vafadar A., Naderi S. et al. Escherichia coli cytosine deaminase: structural and biotechnological aspects. Biotechnol Appl Biochem 2024;71(1):5–16. doi: 10.1002/bab.2516
  23. Aučynaitė A., Rutkienė R., Tauraitė D. et al. Discovery of bacterial deaminases that convert 5-fluoroisocytosine into 5-fluorouracil. Front Microbiol 2018;9:2375. doi: 10.3389/fmicb.2018.02375
  24. Ho Y.K., Woo J.Y., Tu G.X.E. et al. A highly efficient non-viral process for programming mesenchymal stem cells for gene directed enzyme prodrug cancer therapy. Sci Rep 2020;10(1):14257. doi: 10.1038/s41598-020-71224-2
  25. Xu N., Tian H., Po Fung C. et al. Inhibition of human oral squamous cell carcinoma proliferation and migration by prodrug-activating suicide gene therapies. Exp Ther Med 2023;25(2):92. doi: 10.3892/etm.2023.11790
  26. Horikawa M., Koizumi S., Oishi T. et al. Potent bystander effect and tumor tropism in suicide gene therapy using stem cells from human exfoliated deciduous teeth. Cancer Gene Ther 2023;30(1):85–95. doi: 10.1038/s41417-022-00527-5
  27. Tanaka T., Duflot-Dancer A., Tiraby M. et al. Bystander effect from cytosine deaminase and uracil phosphoribosyl transferase genes in vitro: a partial contribution of gap junctions. Cancer Lett 2009;282(1):43–7. doi: 10.1016/j.canlet.2009.02.050
  28. Oishi T., Ito M., Koizumi S. et al. Efficacy of HSV-TK/GCV system suicide gene therapy using SHED expressing modified HSV-TK against lung cancer brain metastases. Mol Ther Methods Clin Dev 2022;26:253–65. doi: 10.1016/j.omtm.2022.07.001
  29. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type 1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum Gene Ther 2000;11(17):2389–401. doi: 10.1089/104303400750038499
  30. Fabbrini M.S., Katayama M., Nakase I., Vago R. Plant ribosomeinactivating proteins: progesses, challenges and biotechnological applications (and a few digressions). Toxins (Basel) 2017;9(10):314. doi: 10.3390/toxins9100314
  31. Pahle J., Menzel L., Niesler N. et al. Rapid eradication of colon carcinoma by Clostridium perfringens enterotoxin suicidal gene therapy. BMC Cancer 2017;17(1):129. doi: 10.1186/s12885-017-3123-x
  32. Piontek A., Eichner M., Zwanziger D. et al. Targeting claudinoverexpressing thyroid and lung cancer by modified Clostridium perfringens enterotoxin. Mol Oncol 2020;14(2):261–76. doi: 10.1002/1878-0261.12615
  33. Pahle J., Kobelt D., Aumann J. et al. Effective oncoleaking treatment of pancreatic cancer by claudin-targeted suicide gene therapy with Clostridium perfringens enterotoxin (CPE). Cancers (Basel) 2021;13(17):4393. doi: 10.3390/cancers13174393
  34. Bagga S., Seth D., Batra J.K. The cytotoxic activity of ribosomeinactivating protein saporin-6 is attributed to its rRNA N-glycosidase and internucleosomal DNA fragmentation activities. J Biol Chem 2003;278(7):4813–20. doi: 10.1074/jbc.M207389200
  35. Sama S., Woith E., Walther W. et al. Targeted suicide gene transfections reveal promising results in nu/nu mice with aggressive neuroblastoma. J Control Release 2018;275:208–16. doi: 10.1016/j.jconrel.2018.02.031
  36. Herawati I.E., Lesmana R., Levita J., Subarnas A. Cytotoxicity, apoptosis, migration inhibition, and autophagy-induced by crude ricin from ricinus communis seeds in a549 lung cancer cell lines. Med Sci Monit Basic Res 2022;28:e936683. doi: 10.12659/MSMBR.936683
  37. Morgan R.N., Saleh S.E., Farrag H.A., Aboshanab K.M. New insights on Pseudomonas aeruginosa exotoxin A-based immunotoxins in targeted cancer therapeutic delivery. Ther Deliv 2023;14(1):31–60. doi: 10.4155/tde-2022-0055
  38. Dai L., Yu X., Huang S. et al. The therapeutic potential of attenuated diphtheria toxin delivered by an adenovirus vector with survivin promoter on human lung cancer cells. Cancer Biol Ther 2021;22(1):79–87. doi: 10.1080/15384047.2020.1859870
  39. Zinser E., Rössner S., Littmann L. et al. The IL-2 diphtheria toxin fusion protein denileukin diftitox modulates the onset of diabetes in female nonobese diabetic animals in a time-dependent manner and breaks tolerance in male nonobese diabetic animals. J Immunol 2012;189(3):1173–81. doi: 10.4049/jimmunol.1102691
  40. Pemmaraju N., Konopleva M. Approval of tagraxofusp-erzs for blastic plasmacytoid dendritic cell neoplasm. Blood Adv 2020;4(16):4020–7. doi: 10.1182/bloodadvances.2019000173
  41. Dhillon S. Moxetumomab pasudotox: first global approval. Drugs 2018;78(16):1763–7. doi: 10.1007/s40265-018-1000-9
  42. Dieffenbach M., Pastan I. Mechanisms of resistance to immunotoxins containing Pseudomonas exotoxin a in cancer therapy. Biomolecules 2020;10(7):979. doi: 10.3390/biom10070979
  43. Cerise A., Bera T.K., Liu X. et al. Anti-mesothelin recombinant immunotoxin therapy for colorectal cancer. Clin Colorectal Cancer 2019;18(3):192–9. doi: 10.1016/j.clcc.2019.06.006
  44. Granot-Matok Y., Ezra A., Ramishetti S. et al. Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors. Theranostics 2023;13(11):3497–508. doi: 10.7150/thno.82228
  45. Nakashima I., Saito S., Akahoshi E. et al. Non-viral inducible caspase 9 mRNA delivery using lipid nanoparticles against breast cancer: an in vitro study. Biochem Biophys Res Commun 2022;635:144–53. doi: 10.1016/j.bbrc.2022.09.105
  46. Pathak S., Singh V., Kumar N., Jayandharan G.R. Inducible caspase 9-mediated suicide gene therapy using AAV6 vectors in a murine model of breast cancer. Mol Ther Methods Clin Dev 2023;31:101166. doi: 10.1016/j.omtm.2023.101166
  47. Long Q., Yang R., Lu W. et al. Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells. Oncol Rep 2017;37(1):155–62. doi: 10.3892/or.2016.5263
  48. Garg H., Salcedo R., Trinchieri G., Blumenthal R. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. Cancer Gene Ther 2010;17(3):155–63. doi: 10.1038/cgt.2009.63
  49. Rossignoli F., Grisendi G., Spano C. et al. Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy. Cancer Gene Ther 2019;26(1–2):11–6. doi: 10.1038/s41417-018-0034-1
  50. Moradi-Mehr S., Khademy M., Akbari-Birgani S. et al. Comparative evaluation of the therapeutic strategies using a minimal model of luminal-A breast cancer. Biochem Biophys Res Commun 2023;666:107–14. doi: 10.1016/j.bbrc.2023.05.028
  51. Shariat S.F., Desai S., Song W. et al. Adenovirus-mediated transfer of inducible caspases: a novel “death switch” gene therapeutic approach to prostate cancer. Cancer Res 2001;61(6):2562–71.
  52. Kemper K., Rodermond H., Colak S. et al. Targeting colorectal cancer stem cells with inducible caspase-9. Apoptosis 2012;17(5):528–37. doi: 10.1007/s10495-011-0692-z
  53. Montaño-Samaniego M., Bravo-Estupiñan D.M., Méndez-Guerrero O. et al. Strategies for targeting gene therapy in cancer cells with tumor-specific promoters. Front Oncol 2020;10:605380. doi: 10.3389/fonc.2020.605380
  54. Ji X., Zhang J., Cheng L. et al. Oncolytic adenovirus delivering herpes simplex virus thymidine kinase suicide gene reduces the growth of human retinoblastoma in an in vivo mouse model. Exp Eye Res 2009;89(2):193–9. doi: 10.1016/j.exer.2009.03.007
  55. Peng W., Chen J., Huang Y.H., Sawicki J.A. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells. Gene Ther 2005;12(21):1573–80. doi: 10.1038/sj.gt.3302580
  56. Yahya E.B., Alqadhi A.M. Recent trends in cancer therapy : a review on the current state of gene delivery. Life Sci 2021;269:119087. doi: 10.1016/j.lfs.2021.119087
  57. Li X., Le Y., Zhang Z. et al. Viral vector-based gene therapy. Int J Mol Sci 2023;24(9):7736. doi: 10.3390/ijms24097736
  58. Greig J.A., Martins K.M., Breton C. et al. Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration. Nat Biotechnol 2023. doi: 10.1038/s41587-023-01974-7
  59. Zweiri J., Christmas S.E. Demonstration of anti-tumour bystander killing with prodrug-preloaded suicide gene-engineered tumour cells: a potential improvement for cancer therapeutics. Cancer Cell Int 2020;20:26. doi: 10.1186/s12935-020-1115-4
  60. Srivastava A., Mallela K.M.G., Deorkar N., Brophy G. Manufacturing challenges and rational formulation development for AAV viral vectors. J Pharm Sci 2021;110(7):2609–24. doi: 10.1016/j.xphs.2021.03.024
  61. Nguyen Q.M., Dupré P.F., Haute T. et al. Suicide gene strategies applied in ovarian cancer studies. Cancer Gene Ther 2023;30(6):812–21. doi: 10.1038/s41417-023-00590-6
  62. Ghasempour E., Hesami S., Movahed E. et al. Mesenchymal stem cell-derived exosomes as a new therapeutic strategy in the brain tumors. Stem Cell Res Ther 2022;13(1):527. doi: 10.1186/s13287-022-03212-4
  63. Oraee-Yazdani S., Tavanaei R., Rostami F. et al. Suicide gene therapy using allogeneic adipose tissue-derived mesenchymal stem cell gene delivery vehicles in recurrent glioblastoma multiforme: a first-in-human, dose-escalation, phase I clinical trial. J Transl Med 2023;21(1):350. doi: 10.1186/s12967-023-04213-4
  64. Hendijani F., Javanmard S.H., Sadeghi-aliabadi H. Human Wharton’s jelly mesenchymal stem cell secretome display antiproliferative effect on leukemia cell line and produce additive cytotoxic effect in combination with doxorubicin. Tissue Cell 2015;47(3):229–34. doi: 10.1016/j.tice.2015.01.005
  65. Makarov A.A., Kolchinsky A., Ilinskaya O.N. Binase and other microbial RNases as potential anticancer agents. Bioessays 2008;30(8):781–90. doi: 10.1002/bies.20789
  66. Dudkina E.V., Ulyanova V.V., Ilinskaya O.N. Supramolecular organization as a factor of ribonuclease cytotoxicity. Acta Naturae 2020;12(3):24–33. doi: 10.32607/actanaturae.11000
  67. Mitkevich V.A., Burnysheva K.M, Petrushanko I.Y. et al. Binase treatment increases interferon sensitivity and apoptosis in SiHa cervical carcinoma cells by downregulating E6 and E7 human papilloma virus oncoproteins. Oncotarget 2017;8(42): 72666–75. doi: 10.18632/oncotarget.20199
  68. Mitkevich V.A., Kretova O.V., Petrushanko I.Y. et al. Ribonuclease binase apoptotic signature in leukemic Kasumi-1 cells. Biochimie 2013;95(6):1344–9. doi: 10.1016/j.biochi.2013.02.016
  69. Ilinskaya O.N., Singh I., Dudkina E. et al. Direct inhibition of oncogenic KRAS by Bacillus pumilus ribonuclease (binase). Biochim Biophys Acta 2016;1863(7 Pt. A):1559–67. doi: 10.1016/j.bbamcr.2016.04.005
  70. Mironova N.L., Petrushanko I.Y., Patutina O.A. et al. Ribonuclease binase inhibits primary tumor growth and metastases via apoptosis induction in tumor cells. Cell Cycle 2013;12(13):2120–31. doi: 10.4161/cc.25164
  71. Dudkina E., Ulyanova V., Asmandiyarova V. et al. Two main cancer biomarkers as molecular targets of binase antitumor activity. Biomed Res Int 2024;2024:8159893. doi: 10.1155/2024/8159893
  72. Mitkevich V.A., Tchurikov N.A., Zelenikhin P.V. et al. Binase cleaves cellular noncoding RNAs and affects coding mRNAs. FEBS J 2010;277(1):186–96. doi: 10.1111/j.1742-4658.2009.07471.x
  73. Sokurenko J.V., Zelenikhin P.V., Ulyanova V.V. et al. Identification of 2’,3’-cGMP as an intermediate of RNA catalytic cleavage by binase and evaluation of its biological action. Bioorg Khim 2015;41(1):37–43. doi: 10.1134/s1068162015010136
  74. Azarashvili T., Krestinina O., Galvita A. et al. Ca2+-dependent permeability transition regulation in rat brain mitochondria by 2’,3’-cyclic nucleotides and 2’,3’-cyclic nucleotide 3’-phosphodiesterase. Am J Physiol Cell Physiol 2009;296(6):C1428–39. doi: 10.1152/ajpcell.00006.2009
  75. Cabrera Fuentes H.A., Kalacheva N.V., Mukhametshina R.T. et al. Binase penetration into alveolar epithelial cells does not induce cell death. Biomed Khim 2012;58(3):272–80. doi: 10.18097/pbmc20125803272
  76. Ilinskaya O.N., Zelenikhin P.V., Petrushanko I.Y. et al. Binase induces apoptosis of transformed myeloid cells and does not induce T-cell immune response. Biochem Biophys Res Commun 2007;361(4):1000–5. doi: 10.1016/j.bbrc.2007.07.143

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ,


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 57560 от  08.04.2014.